CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
0.8755
8.69%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.0150
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026235 %
Charges from full value of position ($-4.98)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026235%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.004012 %
Charges from full value of position ($0.76)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004012%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Adverum Biotechnologies Inc ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 0.8055
Open* 0.8076
1-Year Change* 22.94%
Day's Range* 0.7855 - 0.8817
52 wk Range 0.53-2.34
Average Volume (10 days) 178.78K
Average Volume (3 months) 4.95M
Market Cap 86.88M
P/E Ratio -100.00K
Shares Outstanding 101.03M
Revenue 3.60M
EPS -1.26
Dividend (Yield %) N/A
Beta 0.75
Next Earnings Date Mar 28, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 1, 2023 0.8055 0.0050 0.62% 0.8005 0.8087 0.7755
Nov 30, 2023 0.8042 -0.0063 -0.78% 0.8105 0.8186 0.7955
Nov 29, 2023 0.8155 0.0000 0.00% 0.8155 0.8255 0.8100
Nov 28, 2023 0.8105 -0.0355 -4.20% 0.8460 0.8465 0.8015
Nov 27, 2023 0.8456 -0.0369 -4.18% 0.8825 0.8825 0.8361
Nov 24, 2023 0.8751 0.0496 6.01% 0.8255 0.8751 0.8255
Nov 22, 2023 0.8357 -0.0298 -3.44% 0.8655 0.8855 0.8255
Nov 21, 2023 0.8555 -0.0401 -4.48% 0.8956 0.8956 0.8555
Nov 20, 2023 0.9093 0.0238 2.69% 0.8855 0.9186 0.8655
Nov 17, 2023 0.8955 0.0300 3.47% 0.8655 0.8972 0.8455
Nov 16, 2023 0.8755 0.0394 4.71% 0.8361 0.8850 0.8361
Nov 15, 2023 0.8756 0.0401 4.80% 0.8355 0.8756 0.8255
Nov 14, 2023 0.8566 -0.0089 -1.03% 0.8655 0.8956 0.8455
Nov 13, 2023 0.8955 -0.0300 -3.24% 0.9255 0.9255 0.8355
Nov 10, 2023 0.9055 0.0200 2.26% 0.8855 0.9234 0.8782
Nov 9, 2023 0.8956 0.0001 0.01% 0.8955 0.9128 0.8674
Nov 8, 2023 0.8955 0.0000 0.00% 0.8955 0.9510 0.8701
Nov 7, 2023 0.9055 -0.0600 -6.21% 0.9655 0.9655 0.8935
Nov 6, 2023 0.9455 -0.1500 -13.69% 1.0955 1.0955 0.9455
Nov 3, 2023 0.9267 -0.0688 -6.91% 0.9955 0.9955 0.9267

Adverum Biotechn Events

Time (UTC) Country Event
Thursday, March 28, 2024

Time (UTC)

10:59

Country

US

Event

Q4 2023 Adverum Biotechnologies Inc Earnings Release
Q4 2023 Adverum Biotechnologies Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0 7.5 0 0.25 1.612
Revenue 0 7.5 0 0.25 1.612
Total Operating Expense 157.135 153.622 117.95 68.795 79.693
Selling/General/Admin. Expenses, Total 55.758 63.341 44.641 28.376 24.56
Research & Development 99.277 89.181 73.309 40.419 50.133
Unusual Expense (Income) 2.1 1.1 0 5
Operating Income -157.135 -146.122 -117.95 -68.545 -78.081
Interest Income (Expense), Net Non-Operating
Other, Net 2.673 0.582 1.557 4.059 4.204
Net Income Before Taxes -154.462 -145.54 -116.393 -64.486 -73.877
Net Income After Taxes -154.536 -145.54 -117.507 -64.486 -72.627
Net Income Before Extra. Items -154.536 -145.54 -117.507 -64.486 -72.627
Net Income -154.536 -145.54 -117.507 -64.486 -72.627
Income Available to Common Excl. Extra. Items -154.536 -145.54 -117.507 -64.486 -72.627
Income Available to Common Incl. Extra. Items -154.536 -145.54 -117.507 -64.486 -72.627
Diluted Net Income -154.536 -145.54 -117.507 -64.486 -72.627
Diluted Weighted Average Shares 99.251 98.039 85.146 64.102 61.375
Diluted EPS Excluding Extraordinary Items -1.55702 -1.48451 -1.38006 -1.00599 -1.18333
Diluted Normalized EPS -1.54327 -1.47329 -1.38006 -1.00599 -1.13038
Total Extraordinary Items
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 3.6 0 0 0
Revenue 0 3.6 0 0 0
Total Operating Expense 33.065 33.839 33.94 41.037 44.025
Selling/General/Admin. Expenses, Total 12.466 12.78 9.641 17.188 13.76
Research & Development 20.599 21.059 22.199 23.849 28.265
Operating Income -33.065 -30.239 -33.94 -41.037 -44.025
Other, Net 1.576 1.2 1.223 0.923 0.283
Net Income Before Taxes -31.489 -29.039 -32.717 -40.114 -43.742
Net Income After Taxes -31.51 -29.056 -32.736 -40.131 -43.761
Net Income Before Extra. Items -31.51 -29.056 -32.736 -40.131 -43.761
Net Income -31.51 -29.056 -32.736 -40.131 -43.761
Income Available to Common Excl. Extra. Items -31.51 -29.056 -32.736 -40.131 -43.761
Income Available to Common Incl. Extra. Items -31.51 -29.056 -32.736 -40.131 -43.761
Diluted Net Income -31.51 -29.056 -32.736 -40.131 -43.761
Diluted Weighted Average Shares 100.768 100.304 99.923 99.475 99
Diluted EPS Excluding Extraordinary Items -0.3127 -0.28968 -0.32761 -0.40343 -0.44203
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.3127 -0.28968 -0.31395 -0.40343 -0.4289
Unusual Expense (Income) 2.1 0 2
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 190.595 317.145 434.438 175.87 208.754
Cash and Short Term Investments 185.589 305.188 429.729 166.035 205.079
Cash & Equivalents 68.431 34.195 62.424 65.897 154.949
Total Receivables, Net 0 5.709
Prepaid Expenses 5.006 6.248 4.709 9.835 3.675
Total Assets 308.372 439.727 482.567 222.727 213.495
Property/Plant/Equipment, Total - Net 113.861 119.06 47.101 45.847 3.586
Property/Plant/Equipment, Total - Gross 130.855 132.234 57.173 53.839 10.008
Accumulated Depreciation, Total -16.994 -13.174 -10.072 -7.992 -6.422
Intangibles, Net 0
Other Long Term Assets, Total 3.916 2.753 1.028 1.01 1.155
Total Current Liabilities 32.246 21.32 20.871 19.408 10.719
Accounts Payable 2.238 1.387 2.81 4.103 1.707
Accrued Expenses 29.754 18.615 18.061 15.305 8.784
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.254 1.318 0.228
Total Liabilities 126.854 123.542 48.22 47.77 12.328
Total Long Term Debt 0 0 0 0 0
Deferred Income Tax 0
Other Liabilities, Total 94.608 102.222 27.349 28.362 1.609
Total Equity 181.518 316.185 434.347 174.957 201.167
Common Stock 0.01 0.01 0.01 0.007 0.006
Additional Paid-In Capital 985.651 964.965 937.134 560.704 522.503
Retained Earnings (Accumulated Deficit) -802.612 -648.076 -502.536 -385.029 -320.543
Other Equity, Total -1.531 -0.714 -0.261 -0.725 -0.799
Total Liabilities & Shareholders’ Equity 308.372 439.727 482.567 222.727 213.495
Total Common Shares Outstanding 100.117 98.381 97.549 67.329 62.9655
Short Term Investments 117.158 270.993 367.305 100.138 50.13
Preferred Stock - Non Redeemable, Net 0 0 0
Note Receivable - Long Term 0 0.769
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 124.596 147.143 168.873 190.595 213.243
Cash and Short Term Investments 117.082 141.453 164.285 185.589 203.264
Cash & Equivalents 105.366 111.187 67.552 68.431 84.43
Short Term Investments 11.716 30.266 96.733 117.158 118.834
Prepaid Expenses 7.514 5.69 4.588 5.006 9.979
Total Assets 196.77 241.429 275.577 308.372 332.362
Property/Plant/Equipment, Total - Net 68.254 90.328 102.85 113.861 116.461
Property/Plant/Equipment, Total - Gross 81.756 110.448 121.436 130.855 133.855
Accumulated Depreciation, Total -13.502 -20.12 -18.586 -16.994 -17.394
Other Long Term Assets, Total 3.92 3.958 3.854 3.916 2.658
Total Current Liabilities 28.856 44.518 46.472 32.246 28.621
Accounts Payable 2.17 1.418 2.863 2.238 0.846
Accrued Expenses 26.584 43.029 43.345 29.754 27.474
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 94.056 110.274 117.82 126.854 124.025
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 65.2 65.756 71.348 94.608 95.404
Total Equity 102.714 131.155 157.757 181.518 208.337
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 0.01 0.01 0.01 0.01 0.01
Additional Paid-In Capital 999.319 994.929 990.214 985.651 980.156
Retained Earnings (Accumulated Deficit) -896.063 -863.178 -831.668 -802.612 -769.876
Other Equity, Total -0.552 -0.606 -0.799 -1.531 -1.953
Total Liabilities & Shareholders’ Equity 196.77 241.429 275.577 308.372 332.362
Total Common Shares Outstanding 101.027 100.993 100.573 100.117 99.728
Total Receivables, Net 0 0
Other Current Liabilities, Total 0.102 0.071 0.264 0.254 0.301
Note Receivable - Long Term 0 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -154.536 -145.54 -117.507 -64.486 -72.627
Cash From Operating Activities -108.091 -107.831 -79.291 -49.17 -53.964
Cash From Operating Activities 6.528 4.645 4.158 1.573 1.75
Non-Cash Items 20.028 29.002 21.329 8.684 18.534
Changes in Working Capital 19.889 4.062 12.729 5.059 -0.371
Cash From Investing Activities 141.72 78.709 -280.167 -68.073 69.444
Capital Expenditures -11.816 -15.123 -11.844 -19.247 -0.809
Other Investing Cash Flow Items, Total 153.536 93.832 -268.323 -48.826 70.253
Cash From Financing Activities 0.607 2.397 355.985 28.191 69.949
Financing Cash Flow Items 0 -2.043 -1.47 -1.191
Issuance (Retirement) of Stock, Net 0.607 2.637 358.089 29.773 71.215
Issuance (Retirement) of Debt, Net 0 -0.24 -0.061 -0.112 -0.075
Foreign Exchange Effects 0
Net Change in Cash 34.236 -26.725 -3.473 -89.052 85.429
Deferred Taxes 0 -1.25
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -29.056 -154.536 -121.8 -81.669 -37.908
Cash From Operating Activities -22.412 -108.091 -89.616 -57.808 -28.929
Cash From Operating Activities 1.592 6.528 4.816 3.028 1.425
Non-Cash Items 3.622 20.028 15.135 12.617 5.501
Changes in Working Capital 1.43 19.889 12.233 8.216 2.053
Cash From Investing Activities 21.533 141.72 139.486 115.118 84.383
Capital Expenditures -0.085 -11.816 -11.631 -10.807 -4.374
Other Investing Cash Flow Items, Total 21.618 153.536 151.117 125.925 88.757
Cash From Financing Activities 0 0.607 0.365 0.365 0.003
Financing Cash Flow Items
Issuance (Retirement) of Stock, Net 0 0.607 0.365 0.365 0.003
Issuance (Retirement) of Debt, Net 0 0 0 0
Net Change in Cash -0.879 34.236 50.235 57.675 55.457
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Commodore Capital LP Hedge Fund 9.9017 10000000 3841859 2023-06-30 MED
Fidelity Management & Research Company LLC Investment Advisor 7.685 7761292 -8532 2023-06-30 LOW
Morgan Stanley & Co. LLC Research Firm 6.893 6961467 -1610 2023-06-30 MED
VR Adviser, LLC Venture Capital 5.8415 5899489 2013243 2023-07-14 MED
BofA Global Research (US) Research Firm 5.5368 5591790 0 2023-06-30 LOW
Versant Ventures Venture Capital 5.0184 5068233 0 2023-06-30 LOW
Goldman Sachs & Company, Inc. Research Firm 4.5163 4561168 3509 2023-06-30 MED
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 4.0221 4062034 -81097 2023-06-30 LOW
BML Capital Management LLC Investment Advisor 3.8765 3915000 -1242179 2023-09-30 HIGH
Sonic GP LLC Hedge Fund 1.9803 2000000 0 2023-06-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 1.3172 1330314 -336287 2023-06-30 LOW
Renaissance Technologies LLC Hedge Fund 1.2047 1216641 79900 2023-06-30 HIGH
AIGH Capital Management, LLC. Private Equity 1.1019 1112874 211434 2023-06-30 MED
Newtyn Management, LLC Hedge Fund 0.9902 1000000 -528400 2023-06-30 MED
Two Sigma Investments, LP Hedge Fund 0.9036 912540 -384567 2023-06-30 HIGH
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.8783 887046 99146 2023-06-30 LOW
Fischer (Laurent D M.D.) Individual Investor 0.7977 805574 125433 2023-04-01 LOW
Bellecapital Partners AG Investment Advisor/Hedge Fund 0.5377 543035 0 2023-02-28 LOW
Quinn Opportunity Partners LLC Hedge Fund 0.3944 398298 0 2023-06-30 HIGH
Worth Venture Partners, LLC Investment Advisor/Hedge Fund 0.367 370683 72123 2023-06-30 HIGH

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Adverum Biotechn Company profile

About Adverum Biotechnologies Inc

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company targeting ocular and rare diseases. It develops gene therapy product candidates. Its ADVM-022, is a clinical-stage gene therapy product candidate developed for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). ADVM-022, is given as a one-time in-office intravitreal (IVT) injection and is designed to reduce the burden of anti-vascular endothelial growth factor (anti-VEGF) injections, optimize patient compliance and improve vision outcomes for patients with wet AMD or DME. It is conducting the OPTIC trial, designed as a multi-center, open-label, Phase I, dose-ranging safety trial of ADVM-022 in patients with wet AMD, who have demonstrated responsiveness to anti-VEGF treatment. It is also conducting the INFINITY trial, a multi-center, Phase II, randomized, double-masked, active comparator-controlled study evaluating a single IVT injection of ADVM-022 in patients with DME.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Adverum Biotechnologies Inc revenues increased from $0K to $7.5M. Net loss increased 39% to $111.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative - Balancing increase of 74% to $37.8M (expense), Research and development -gross increase of 31% to $59.5M (expense).

Industry: Bio Therapeutic Drugs

100 Cardinal Way
REDWOOD CITY
CALIFORNIA 94063
US

Income Statement

  • Annual
  • Quarterly

News

December RBA preview: no move expected at the final meeting of 2023

The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

14:47, 4 December 2023

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023

Crude prices slide on OPEC+ uncertainty

Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

12:55, 28 November 2023

People also watch

Oil - Crude

73.39 Price
-1.410% 1D Chg, %
Long position overnight fee -0.0200%
Short position overnight fee -0.0019%
Overnight fee time 22:00 (UTC)
Spread 0.030

US100

15,819.20 Price
-1.100% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 1.8

BTC/USD

41,963.20 Price
+5.490% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Gold

2,029.27 Price
-2.040% 1D Chg, %
Long position overnight fee -0.0200%
Short position overnight fee 0.0118%
Overnight fee time 22:00 (UTC)
Spread 0.50

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading